Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.

Gimeno-Pitarch L, Iborra M, Crespo A, Sanchis L, Antón MR, Pastor M, Martí L, Herreros B, Peña C, Ruíz L, Almudena Pérez A, Díaz FC, Maroto N, Laveda R, Madero L, Buendía L, Nos P

Open source

DOI
10.1093/ecco-jcc/jjag067
Published
2026 Jun 7
Container
Journal of Crohn's & colitis
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ecco-jcc/jjag067,
  title = {Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.},
  author = {Gimeno-Pitarch L and Iborra M and Crespo A and Sanchis L and Antón MR and Pastor M and Martí L and Herreros B and Peña C and Ruíz L and Almudena Pérez A and Díaz FC and Maroto N and Laveda R and Madero L and Buendía L and Nos P},
  year = {2026},
  journal = {Journal of Crohn's \& colitis},
  doi = {10.1093/ecco-jcc/jjag067},
  url = {https://doi.org/10.1093/ecco-jcc/jjag067}
}

RIS

TY  - JOUR
TI  - Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.
AU  - Gimeno-Pitarch L
AU  - Iborra M
AU  - Crespo A
AU  - Sanchis L
AU  - Antón MR
AU  - Pastor M
AU  - Martí L
AU  - Herreros B
AU  - Peña C
AU  - Ruíz L
AU  - Almudena Pérez A
AU  - Díaz FC
AU  - Maroto N
AU  - Laveda R
AU  - Madero L
AU  - Buendía L
AU  - Nos P
PY  - 2026
JO  - Journal of Crohn's & colitis
DO  - 10.1093/ecco-jcc/jjag067
UR  - https://doi.org/10.1093/ecco-jcc/jjag067
ER  - 

APA

L, G., M, I., A, C., L, S., MR, A., M, P., L, M., B, H., C, P., L, R., A, A. P., FC, D., N, M., R, L., L, M., L, B., & P, N. (2026). Risk of symptomatic leishmaniasis in patients with inflammatory bowel disease receiving biologic therapy in an endemic Mediterranean region: a population-based case-control study.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjag067

Source records